Oric Pharmaceuticals Stock Cash And Equivalents
| ORIC Stock | USD 9.80 0.07 0.71% |
Oric Pharmaceuticals fundamentals help investors to digest information that contributes to Oric Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oric Stock. The fundamental analysis module provides a way to measure Oric Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oric Pharmaceuticals stock.
Oric | Cash And Equivalents |
Oric Pharmaceuticals Company Cash And Equivalents Analysis
Oric Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Oric Pharmaceuticals Cash And Equivalents | 227.06 M |
Most of Oric Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oric Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oric Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Oric Pharmaceuticals is extremely important. It helps to project a fair market value of Oric Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Oric Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oric Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oric Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Oric Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Oric Pharmaceuticals has 227.06 M in Cash And Equivalents. This is 72.34% lower than that of the Biotechnology sector and 49.22% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 91.6% higher than that of the company.
Oric Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oric Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oric Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics of similar companies.Oric Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Oric Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oric Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oric Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Oric Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 407.49 M | ||||
| Shares Outstanding | 70.57 M | ||||
| Shares Owned By Insiders | 9.12 % | ||||
| Shares Owned By Institutions | 90.88 % | ||||
| Number Of Shares Shorted | 11.65 M | ||||
| Price To Book | 2.47 X | ||||
| EBITDA | (109.75 M) | ||||
| Net Income | (100.7 M) | ||||
| Cash And Equivalents | 227.06 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 10.21 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 18.72 X | ||||
| Book Value Per Share | 3.88 X | ||||
| Cash Flow From Operations | (85.69 M) | ||||
| Short Ratio | 29.34 X | ||||
| Earnings Per Share | (1.87) X | ||||
| Target Price | 18.73 | ||||
| Number Of Employees | 112 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 696.5 M | ||||
| Total Asset | 252.01 M | ||||
| Retained Earnings | (434.93 M) | ||||
| Working Capital | 192.14 M | ||||
| Net Asset | 252.01 M |
About Oric Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oric Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oric Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oric Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Oric Pharmaceuticals Piotroski F Score and Oric Pharmaceuticals Altman Z Score analysis. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.